Feline immune-mediated diseases


Ekaterina S. Mendoza-Kuznetsova

Immunemediated

Autoimmune


Autoimmune diseases

Pemphigus





Pemphigoids


Lupus erythematosus



Pemphigus, desmosome composition







2010

Pemphigus foliaceus (PF)

Bizikova and Burrows *BMC Veterinary Research* https://doi.org/10.1186/s12917-018-1739-y

(2019) 15:22

BMC Veterinary Research

RESEARCH ARTICLE

Open Access

Feline pemphigus foliaceus: original case series and a comprehensive literature review

CrossMark

Petra Bizikova^{1,2*} and Amanda Burrows³

Vet Dermatol 2019; 30: 209-e65

DOI: 10.1111/vde.12731

Clinicopathological findings and clinical outcomes in 49 cases of feline pemphigus foliaceus examined in Northern California, USA (1987–2017)

Tyler J.M. Jordan* (D), Verena K. Affolter† (D), Catherine A. Outerbridge‡, Elizabeth C. Goodale§ (D) and Stephen D. White‡ (D)

Pemphigus foliaceus (PF) Signalments

- The most common pemphigus
- The most common autoimmune disease
- Wide range of onset age (0.4-17 years)
 - Middle age (median 6-7 years) the most common disease onset
- No breed or sex predisposition
 - DSH, DLH and Siamese are overrepresented
 - Females are slightly overrepresented.

Pemphigus foliaceus (PF) Etiology and pathogenesis


- Spontaneous majority of the cases
- Can be drug-induced/triggered?
 - Cimetidine, doxycycline ...
 - Vaccines?
- Can be disease-induced/associated?
 - Thymoma
 - Leishmaniosis
- The major autoantigen in cats is to be defined
 - Desmoglein-1 in humans
 - Desmocollin-1 in dogs.

Pemphigus foliaceus – clinical presentation


- The primary type of lesions –
 PUSTULE
- The main clinical presentation crust
- The most common and early affected areas:
 - Pinnae
 - Nasal planum
 - The head and face
 - Claw folds (47-74%)
- Can be generalized
- Can be accompanied by systemic signs (50-63%).

Pemphigus foliaceus – diagnosis

- History
 - Non pruritic pustules / crust
 - Pruritus in 31-73% of feline cases
- Clinical presentation
- Cytology
 - The best from intact pustule
 - Acceptable under the superficial crust
 - From claw fold pus
 - Non degenerative neutrophils and acantholytic cells
 - Cytology is not confirmative!



Pemphigus foliaceus – histopathology



Pemphigus foliaceus – treatment

Induction

- The goal to depress immune system enough for the lesions to stop spreading and to start to heal (94%).
- About 1-8 weeks, median 22-41 days Immunosuppressive dose

Maintenance

- The goal to prevent relapses and to support remission
- Months to years

Anti-inflammatory dose

Outcome

- Complete clinical remission and withdrawal of treatment cure (~14-17%)
- Stable remission with life-long maintaining therapy needed
- No or weak response new therapeutic search or euthanasia.

Induction


- Prednisolone (not prednisone!) 2-6.6 mg/kg/day or triamcinolone 0.6-2 mg/kg/day
 - No benefit of pulse therapy (Bizikova, 2017 and 2019)
 - Usually 2-4 weeks to achieve the clinical remission (Simpson and Burton, 2013)
 - 62% in 2 weeks
 - 89% in 4 weeks
- Prednisolone + chlorambucil 0.1-0.2 mg/kg/day or EOD
- Prednisolone + cyclosporine 5-7.5 mg/kg/day
 - Cyclosporine may have a GCS-sparing effect (Irwin et al, Vet Derm 2012).

Maintenance

- Prednisolone:
 - Decrease the dose
 - When the dose is about ½ go to every other day (EOD)
 - Withdraw prednisolone (slowly) if possible
- Other medications:
 - Decrease the dose or go to EOD
- Control adverse effects (in about 30% of cats with PF)
 - Depending on the medication and the dose
 - If adverse effects are serious consider other order or switch the medications
- If lesions are few consider topical treatment.

Putative paraneoplastic pemphigus and myasthenia gravis in a cat with a lymphocytic thymoma

Peter B. Hill*, Phil Brain†, David Collins†, Steve Fearnside† and Thierry Olivry‡





Immune-mediated diseases

Plasma cell pododermatitis

- Uncommon disease
- Unknown etiology
 - Likely infectious or immune-mediated
 - No viral, bacterial or allergic components were found
- Clinical signs are characteristic
 - Early lesions:
 - Scaling of the footpads
 - Softness
 - Later dark color of the deep tissue
 - Eventually ulceration.

Veterinary Dermatology

DOI: 10.1111/j.1365-3164.2010.00869.x

Nasal swelling due to plasma cell infiltrate in a cat without plasma cell pododermatitis

Jan Declercq* and Hendrik De Bosschere[†]

- Sneezing
- Swollen nose
- Conjunctivitis
- Rhinitis
- No lesions on the footpads
- Biopsy was identical to plasma cell pododermatitis
- Responded to AB or resolved spontaneously.

- Cytology plasma cell predominating dermatitis
- Biopsy is important for confirmation
- Treatment:
 - Doxycycline + niacinamide
 - Prednisolone
 - Cyclosporine
 - Surgical excision.

Hypereosinophilic syndrome – human medicine

• Several disorders, all with eosinophilia and with no detectable cause:



- Myeloproliferative clonal expansion in the bone marrow
 - Chronic eosinophilic leukemia
 - Undefined



- Lymphocytic chronic reactive polyclonal hypereosinophilia (due to IL-3, IL-5 and GM-CSF)
- Familial
- Associated
 - Mastocytosis, HIV, IBD and others
- Overlap organ-restricted eosinophilia
- Undefined.

Hypereosinophilic syndrome – cats

- Middle-aged
- Domestic short-hair cats
- Females > males
- Most cats are FeLV-negative.

Hypereosinophilic syndrome – clinical signs

- Gastro-intestinal-related signs:
 - Weight loss
 - Anorexia
 - Diarrhea
 - Vomiting
- Skin signs (not necessary!)
 - Pruritus (excoriations)
 - Erythema
 - Macules (erythematous)
 - Wheals
 - Papules.

Hypereosinophilic syndrome – diagnosis

- Diagnostic criteria have not been validated for cats
 - Peripheral eosinophilia (more than 5x10⁹/L)
 - Bone marrow eosinophilia
 - Tissue infiltration of eosinophils
 - No other detectable cause of eosinophilia
- Bone marrow cytology hyperplasia
 - Differs from eosinophilic leukemia:
 - ↑ myeloid/erythroid ration
 - Anemia
 - ↑ circulating immature eosinophils.

Hypereosinophilic syndrome – treatment

- Prednisolone 1-3 mg/kg SID-BID
- Prednisolone + hydroxycarbamide 15-30 mg/kg SID

Prognosis is poor.


Exfoliative dermatitis (ED). Thymoma or not-thymoma associated.

- The patomechanism is not clear
 - defect of thymic lymphocyte selection or/and maturation is suspected
- ED skin lesions (scales, crust, erythema)
 - head and pinnae, then spread to the neck and the rest of the body.
- The diagnosis: skin histopathology ± finding the thymoma (x-ray, MRI).

Exfoliative dermatitis (ED). Thymoma or not-thymoma associated.

- The patomechanism is not clear
 - defect of thymic lymphocyte selection or/and maturation is suspected
- ED skin lesions (scales, crust, erythema)
 - head and pinnae, then spread to the neck and the rest of the body.
- The diagnosis: skin histopathology ± finding the thymoma (x-ray, MRI)
- The only curative treatment is surgical removal of thymoma (when present and when possible)
- Non-thymoma associated cases can be managed with steroids, cyclosporine or even shampoo.

Erythema multiforme (EM) – Stevens-Johnson syndrome (SJS) – Toxic epidermal necrolysis (TEN)



Erythema multiforme: human medicine

• EM is acute, self-limited, usually mild and often relapsing targetshaped plaques affecting mostly the face and extremities.



